IL233965B - History (2s, 5z, 9r 10s, 20r)-8,7,4,3-tetra-dehydro-18,13,9,2-tetra-hydro-18,13-dioxo-h1- 10,20,10 -(epoxy-methano)anthra[2,1-b]azacyclo-dodecine as anti-cancer drugs and their conjugates with antibodies and antigens - Google Patents
History (2s, 5z, 9r 10s, 20r)-8,7,4,3-tetra-dehydro-18,13,9,2-tetra-hydro-18,13-dioxo-h1- 10,20,10 -(epoxy-methano)anthra[2,1-b]azacyclo-dodecine as anti-cancer drugs and their conjugates with antibodies and antigensInfo
- Publication number
- IL233965B IL233965B IL233965A IL23396514A IL233965B IL 233965 B IL233965 B IL 233965B IL 233965 A IL233965 A IL 233965A IL 23396514 A IL23396514 A IL 23396514A IL 233965 B IL233965 B IL 233965B
- Authority
- IL
- Israel
- Prior art keywords
- derivatives
- epoxymetheno
- azacyclododecine
- tetradehydro
- anthra
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261598143P | 2012-02-13 | 2012-02-13 | |
| US201261653785P | 2012-05-31 | 2012-05-31 | |
| PCT/US2013/025247 WO2013122823A1 (en) | 2012-02-13 | 2013-02-08 | Enediyne compounds, conjugates thereof, and uses and methods therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL233965B true IL233965B (en) | 2018-01-31 |
Family
ID=47722570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL233965A IL233965B (en) | 2012-02-13 | 2014-08-06 | History (2s, 5z, 9r 10s, 20r)-8,7,4,3-tetra-dehydro-18,13,9,2-tetra-hydro-18,13-dioxo-h1- 10,20,10 -(epoxy-methano)anthra[2,1-b]azacyclo-dodecine as anti-cancer drugs and their conjugates with antibodies and antigens |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US8709431B2 (enExample) |
| EP (1) | EP2814829B1 (enExample) |
| JP (1) | JP6113194B2 (enExample) |
| KR (1) | KR101660146B1 (enExample) |
| CN (1) | CN104220441B (enExample) |
| AR (1) | AR089972A1 (enExample) |
| AU (1) | AU2013221873B2 (enExample) |
| BR (1) | BR112014019990A8 (enExample) |
| CA (1) | CA2864420C (enExample) |
| CL (1) | CL2014002096A1 (enExample) |
| CO (1) | CO7061078A2 (enExample) |
| CY (1) | CY1118899T1 (enExample) |
| DK (1) | DK2814829T3 (enExample) |
| EA (1) | EA027925B1 (enExample) |
| ES (1) | ES2615268T3 (enExample) |
| HK (1) | HK1204326A1 (enExample) |
| HR (1) | HRP20170334T1 (enExample) |
| HU (1) | HUE033704T2 (enExample) |
| IL (1) | IL233965B (enExample) |
| LT (1) | LT2814829T (enExample) |
| MX (1) | MX350539B (enExample) |
| PE (1) | PE20141791A1 (enExample) |
| PL (1) | PL2814829T3 (enExample) |
| PT (1) | PT2814829T (enExample) |
| RS (1) | RS55763B1 (enExample) |
| SG (1) | SG11201404667XA (enExample) |
| SI (1) | SI2814829T1 (enExample) |
| SM (1) | SMT201700137T1 (enExample) |
| TW (1) | TW201336851A (enExample) |
| WO (1) | WO2013122823A1 (enExample) |
| ZA (1) | ZA201406723B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| AU2014306592B2 (en) | 2013-08-14 | 2019-04-04 | Bristol-Myers Squibb Company | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents |
| CA2943228C (en) | 2014-03-20 | 2023-03-14 | Bristol-Myers Squibb Company | Stabilized fibronectin based scaffold molecules |
| JP6668345B2 (ja) | 2014-11-21 | 2020-03-18 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 修飾された重鎖定常領域を含む抗体 |
| AU2015349878A1 (en) | 2014-11-21 | 2017-05-25 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
| CA2969067A1 (en) | 2014-11-25 | 2016-06-02 | Bristol-Myers Squibb Company | Novel pd-l1 binding polypeptides for imaging |
| CN107531720A (zh) * | 2015-01-08 | 2018-01-02 | 斯克利普斯研究院 | 抗癌症候选药物 |
| JP2018510864A (ja) | 2015-03-10 | 2018-04-19 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | トランスグルタミナーゼによって結合可能な抗体およびそれによって製造される結合体 |
| DK3303396T5 (da) | 2015-05-29 | 2024-10-07 | Bristol Myers Squibb Co | Antistoffer mod ox40 og anvendelser deraf |
| CN108884147B (zh) | 2015-09-23 | 2024-02-27 | 百时美施贵宝公司 | 结合磷脂酰肌醇蛋白聚糖3的基于纤连蛋白的支架分子 |
| CN107029242A (zh) | 2015-11-03 | 2017-08-11 | 财团法人工业技术研究院 | 抗体药物复合物及其制造方法 |
| CA3008678A1 (en) | 2015-12-21 | 2017-06-29 | Bristol-Myers Squibb Company | Variant antibodies for site-specific conjugation |
| EP3423494A1 (en) | 2016-03-04 | 2019-01-09 | Bristol-Myers Squibb Company | Combination therapy with anti-cd73 antibodies |
| CN106267188B (zh) * | 2016-08-15 | 2025-06-17 | 深圳大学 | 小分子免疫激动剂偶联pd-1抗体的新型抗体及其在抗肿瘤中的应用 |
| US20190218294A1 (en) | 2016-09-09 | 2019-07-18 | Bristol-Myers Squibb Company | Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| US20200299400A1 (en) | 2017-05-25 | 2020-09-24 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
| EP3720504A1 (en) * | 2017-12-06 | 2020-10-14 | Synaffix B.V. | Enediyne conjugates |
| CN110183659B (zh) * | 2018-02-21 | 2022-04-26 | 香港科技大学 | 含有杂环的聚合物、其制备方法及其应用 |
| EP3887397A1 (en) | 2018-11-28 | 2021-10-06 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
| KR102861586B1 (ko) | 2018-11-30 | 2025-09-17 | 브리스톨-마이어스 스큅 컴퍼니 | 글루타민-함유 경쇄 c-말단 연장부를 포함하는 항체, 그의 접합체, 및 방법 및 용도 |
| US12478686B2 (en) | 2018-12-12 | 2025-11-25 | Bristol-Myers Squibb Company | Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses |
| KR20220024123A (ko) | 2019-05-22 | 2022-03-03 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 암의 치료에서 사용하기 위한 기능화된 금 카르벤 나프토퀴논 복합체 |
| WO2021055306A1 (en) | 2019-09-16 | 2021-03-25 | Bristol-Myers Squibb Company | Dual capture method for analysis of antibody-drug conjugates |
| EP4362982A1 (en) | 2021-06-28 | 2024-05-08 | Byondis B.V. | Conjugates comprising phosphoantigens and their use in therapy |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US5144011A (en) | 1981-06-26 | 1992-09-01 | Boston University | Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers |
| US4631190A (en) | 1981-06-26 | 1986-12-23 | Shen Wei C | Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4698420A (en) | 1985-02-25 | 1987-10-06 | Xoma Corporation | Antibody hybrid molecules and process for their preparation |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5281710A (en) * | 1990-08-01 | 1994-01-25 | The Scripps Research Institute | Dynemicin analogs: synthesis, methods of preparation and use |
| US5162330A (en) * | 1990-11-05 | 1992-11-10 | Bristol-Myers Squibb Co. | Dynemicin c antibiotic, its triacetyl derivative and pharmaceutical composition containing same |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US6955811B2 (en) | 1997-11-07 | 2005-10-18 | Trillium Therapeutics Inc. | Methods of inhibiting immune response suppression by administering antibodies to OX-2 |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US6989452B2 (en) | 2001-05-31 | 2006-01-24 | Medarex, Inc. | Disulfide prodrugs and linkers and stabilizers useful therefor |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| IL162835A0 (en) | 2002-01-09 | 2005-11-20 | Medarex Inc | Human monoclonal antibodies against cd30 |
| EP2261244A3 (en) | 2003-04-15 | 2011-02-23 | Glaxosmithkline LLC | Human il-18 substitution mutants and their conjugates |
| MXPA06000798A (es) | 2003-07-22 | 2006-04-07 | Schering Ag | Anticuerpos de rg1 y usos de los mismos. |
| WO2005051976A2 (en) | 2003-11-20 | 2005-06-09 | Ansata Therapeutics, Inc. | Protein and peptide ligation processes and one-step purification processes |
| US8170637B2 (en) * | 2008-05-06 | 2012-05-01 | Neurosky, Inc. | Dry electrode device and method of assembly |
| CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| JP4806680B2 (ja) | 2004-05-19 | 2011-11-02 | メダレックス インコーポレイテッド | 自己犠牲リンカー及び薬剤複合体 |
| US7691962B2 (en) | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| US7714016B2 (en) | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| CA2611814A1 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
| NZ566395A (en) | 2005-09-26 | 2012-03-30 | Medarex Inc | Human monoclonal antibodies to CD70 |
| EP2354163A3 (en) | 2005-09-26 | 2013-04-24 | Medarex, Inc. | Conjugates of duocarmycin and anti-CD70 or anti-PSMA antibodies |
| WO2007038868A2 (en) * | 2005-10-03 | 2007-04-12 | The University Of British Columbia | Novel enediyne compound and uses thereof |
| RS52100B (sr) | 2005-10-26 | 2012-06-30 | Medarex, Inc. | Postupci i jedinjenja za pripremu analoga cc-1065 |
| WO2007059404A2 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
| EA017812B1 (ru) | 2005-12-08 | 2013-03-29 | Медарекс, Инк. | Выделенное моноклональное антитело или его антигенсвязывающий участок, которые связываются с протеинтирозинкиназой 7 ( ptk7) человека, и их применение |
| WO2007067991A2 (en) | 2005-12-08 | 2007-06-14 | Medarex, Inc. | Human monoclonal antibodies to o8e |
| KR100869414B1 (ko) | 2005-12-13 | 2008-11-21 | 야마하 가부시키가이샤 | 건반식 음판 타악기용의 음판 및 그 제조방법, 음판타악기의 음원 유닛 및 건반식 타악기 |
| JP2010502221A (ja) | 2006-09-08 | 2010-01-28 | アンブルックス，インコーポレイテッド | 脊椎動物細胞による非天然アミノ酸の部位特異的組み込み |
| US8481683B2 (en) | 2006-12-01 | 2013-07-09 | Medarex, Inc. | Human antibodies that bind CD22 and uses thereof |
| UY30776A1 (es) | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
| TWI412367B (zh) | 2006-12-28 | 2013-10-21 | 梅達雷克斯有限責任公司 | 化學鏈接劑與可裂解基質以及其之綴合物 |
| AR065404A1 (es) | 2007-02-21 | 2009-06-03 | Medarex Inc | Conjugados farmaco-ligando, los que se unen a citotoxinas potentes, composicion farmaceutica que los contienen y su uso para retardar o detener el crecimiento de un tumor en un mamifero |
| US8865875B2 (en) | 2007-08-22 | 2014-10-21 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions |
| ES2526355T3 (es) | 2007-10-01 | 2015-01-09 | Bristol-Myers Squibb Company | Anticuerpos humanos que se adhieren a mesotelina, y usos de los mismos |
| WO2010087994A2 (en) | 2009-01-30 | 2010-08-05 | Whitehead Institute For Biomedical Research | Methods for ligation and uses thereof |
-
2013
- 2013-02-08 HU HUE13704871A patent/HUE033704T2/en unknown
- 2013-02-08 HK HK15104893.3A patent/HK1204326A1/xx unknown
- 2013-02-08 LT LTEP13704871.6T patent/LT2814829T/lt unknown
- 2013-02-08 EP EP13704871.6A patent/EP2814829B1/en active Active
- 2013-02-08 JP JP2014556700A patent/JP6113194B2/ja not_active Expired - Fee Related
- 2013-02-08 ES ES13704871.6T patent/ES2615268T3/es active Active
- 2013-02-08 KR KR1020147025070A patent/KR101660146B1/ko not_active Expired - Fee Related
- 2013-02-08 CA CA2864420A patent/CA2864420C/en not_active Expired - Fee Related
- 2013-02-08 AR ARP130100431A patent/AR089972A1/es unknown
- 2013-02-08 SI SI201330469T patent/SI2814829T1/sl unknown
- 2013-02-08 MX MX2014009234A patent/MX350539B/es active IP Right Grant
- 2013-02-08 SM SM20170137T patent/SMT201700137T1/it unknown
- 2013-02-08 AU AU2013221873A patent/AU2013221873B2/en not_active Ceased
- 2013-02-08 PT PT137048716T patent/PT2814829T/pt unknown
- 2013-02-08 CN CN201380019853.3A patent/CN104220441B/zh not_active Expired - Fee Related
- 2013-02-08 HR HRP20170334TT patent/HRP20170334T1/hr unknown
- 2013-02-08 PE PE2014001257A patent/PE20141791A1/es not_active Application Discontinuation
- 2013-02-08 SG SG11201404667XA patent/SG11201404667XA/en unknown
- 2013-02-08 DK DK13704871.6T patent/DK2814829T3/en active
- 2013-02-08 EA EA201491447A patent/EA027925B1/ru not_active IP Right Cessation
- 2013-02-08 PL PL13704871T patent/PL2814829T3/pl unknown
- 2013-02-08 BR BR112014019990A patent/BR112014019990A8/pt not_active Application Discontinuation
- 2013-02-08 WO PCT/US2013/025247 patent/WO2013122823A1/en not_active Ceased
- 2013-02-08 TW TW102105196A patent/TW201336851A/zh unknown
- 2013-02-08 RS RS20170239A patent/RS55763B1/sr unknown
- 2013-02-11 US US13/764,226 patent/US8709431B2/en active Active
-
2014
- 2014-03-10 US US14/203,118 patent/US9156850B2/en active Active
- 2014-08-06 IL IL233965A patent/IL233965B/en active IP Right Grant
- 2014-08-07 CL CL2014002096A patent/CL2014002096A1/es unknown
- 2014-08-28 CO CO14189746A patent/CO7061078A2/es unknown
- 2014-09-12 ZA ZA2014/06723A patent/ZA201406723B/en unknown
-
2017
- 2017-03-03 CY CY20171100285T patent/CY1118899T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL233965B (en) | History (2s, 5z, 9r 10s, 20r)-8,7,4,3-tetra-dehydro-18,13,9,2-tetra-hydro-18,13-dioxo-h1- 10,20,10 -(epoxy-methano)anthra[2,1-b]azacyclo-dodecine as anti-cancer drugs and their conjugates with antibodies and antigens | |
| IL229067B (en) | Preparations for injection of lipophilic substances and methods for their preparation | |
| MY170719A (en) | Antibody-drug conjugates | |
| IL233757A0 (en) | Anti '1m e-gi antibodies and methods of using them | |
| SI2796460T1 (sl) | Pirolni šestčlenski derivat heteroarilnega obroča, postopek priprave zanj in medicinske uporabe le-tega | |
| IL232529A0 (en) | Cytotoxic peptides and their drug-conjugated antibodies | |
| EP2670440A1 (en) | Human antibodies and antibody-drug conjugates against cd74 | |
| ZA201404625B (en) | Polycyclic derivatives, preparation method and medical uses thereof | |
| ZA201300685B (en) | Anticancer derivatives,preparation thereof and therapeutic use thereof | |
| ZA201407021B (en) | Novel thienopyrimidine derivatives,processes for the preparation thereof and therapeutic uses thereof | |
| EP2831059A4 (en) | PROCESSES FOR PREPARING TUBULYSIN DERIVATIVES AND CONJUGATES THEREOF | |
| PL2562172T3 (pl) | Pochodne sfelaktonu, ich kompozycje farmaceutyczne, sposoby wytwarzania i zastosowania | |
| ZA201504538B (en) | Anti-lamp1 antibodies and antibody drug conjugates ,and uses thereof | |
| IL229567A0 (en) | Benzylidine-2h benzene [b] [4,1]thiazine-3(4h)-converted ones, their derivatives, and their medical uses | |
| IL238223B (en) | Nanoparticle mhc antigen complex, method for preparation and composition containing it | |
| ZA201500920B (en) | 3-substituted estra-1,3,5(10),16-tetraene derivatives ,methods for the production thereof ,pharmaceutical preparations contaning same,and use thereof for the production of medicaments | |
| EP2683242A4 (en) | EFFICIENT AMOUNT OF (3AR-) 1,3A, 8-TRIMETHYL-1,2,3,3A, 8,8A-HEXAHYDROPYRROLO- [2,3-B] INDOL-5-YL-PHENYL CARBAMATE AND PROCESS THEREFOR | |
| EP2743206A4 (en) | BEVERAGE PREPARATION CAPSULE WITH LEADERS | |
| IL239146A0 (en) | Aminocyclobutane derivatives, methods for their preparation and their use as drugs | |
| EP3003317A4 (en) | Parthenolide derivatives, methods for their preparation and their use as anticancer agents | |
| PT2849745T (pt) | Composição farmacêutica compreendendo (1r,4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-di-hidro-3'h-espiro[ciclo-hexano-1,1'-pirano[3,4,b]indol]-4-amina e ibuprofeno | |
| ZA201206722B (en) | Sealer elements,detonators containing the same, and methods of making | |
| IL230655A0 (en) | N-hetero-ring-substituted amide derivatives, compositions comprising the same and uses thereof | |
| LT2849746T (lt) | Farmacinė kompozicija, apimanti (1r,4r)-6`-fluor-n,n-dimetil-4-fenil-4`,9`-dihidro-3`h-spiro[cikloheksan-1,1`-pirano [3,4,b]indol]-4-aminą ir meloksikamą | |
| EP3077400A4 (en) | FURO[3,4-b]PYRAN COMPOUNDS AND PHARMACEUTICAL USES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |